Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing the Utility of Shortened Read Time of the Abbott Bioline HCV Test to Predict Viremia.

Journal of viral hepatitis·2026
Same author

Clinical Characteristics of Adolescents and Youth Living with HIV Transitioning from Pediatric to Adult Clinics Before and After 18 Years in Asia.

Journal of acquired immune deficiency syndromes (1999)·2026
Same author

Under the Influence: Alcohol, Substance Use and Treatment Adherence in Youth Living with HIV in the Global Adolescent and Young Adult Network of IeDEA (AYANI) Cohort.

AIDS and behavior·2026
Same author

Pseudo-Ischemic ECG Changes in a Patient With Profound Mixed Metabolic Acidosis Due to Metformin Use.

JACC. Case reports·2026
Same author

Non-randomised trial of a hepatitis C same-day test and treat model using antibody test only for people who inject drugs in Armenia, Georgia and Tanzania: a CUTTS HepC study protocol.

BMJ open·2026
Same author

It's Your Right - implementation and outcomes of a co-designed national Australian hepatitis C health promotion campaign.

The International journal on drug policy·2026

Related Experiment Video

Updated: Dec 13, 2025

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.6K

Global hepatitis C elimination: an investment framework.

Alisa Pedrana1, Jessica Howell2, Nick Scott1

  • 1Disease Elimination Program, Burnet Institute, Melbourne, VIC, Australia; School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.

The Lancet. Gastroenterology & Hepatology
|July 31, 2020
PubMed
Summary
This summary is machine-generated.

Low investment hinders hepatitis elimination goals. This framework offers economic strategies for countries to fund hepatitis B and C elimination, achieving substantial cost savings and health benefits by 2030.

More Related Videos

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.6K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.2K

Related Experiment Videos

Last Updated: Dec 13, 2025

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.6K
A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.6K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.2K

Area of Science:

  • Public Health
  • Health Economics
  • Infectious Disease Control

Background:

  • The World Health Organization (WHO) has established global targets for eliminating hepatitis B and C by 2030.
  • Current investment in hepatitis elimination programs is insufficient to meet these targets.
  • A significant gap exists in political commitment and financing for national hepatitis control strategies.

Purpose of the Study:

  • To present a global investment framework to drive political commitment and financing for hepatitis B and C elimination.
  • To outline national and international activities crucial for reducing hepatitis C incidence and mortality.
  • To identify funding sources and economic tools to support country-level investment in hepatitis elimination.

Main Methods:

  • Development of a comprehensive global investment framework for hepatitis elimination.
  • Analysis of potential funding sources and economic justification for investment.
  • Identification of key national and international activities for disease reduction.

Main Results:

  • The framework provides a strategic approach for countries to invest in hepatitis elimination.
  • It highlights the substantial economic benefits and cost savings associated with hepatitis C elimination.
  • The framework offers tools to build a strong economic case for national hepatitis elimination initiatives.

Conclusions:

  • Investing in hepatitis C elimination yields significant economic advantages and cost savings, particularly for resource-limited nations.
  • The developed framework can catalyze the necessary political will and financial resources for achieving global hepatitis elimination targets.
  • Enhanced investment is critical to realizing the WHO's 2030 goals for hepatitis B and C elimination.